Valion Bio Inc (VBIO) Stock Analysis

Verdict: AVOID

Extreme cash burn and $17.4M debt force toxic preferred financing and severe dilution — the swing risk is a CDMO asset sale or BARDA contract.

Investment score: 11/100

Analysis as of

Is Valion Bio Inc stock worth reviewing? The TradeMates thesis

Valion Bio faces critical liquidity depletion and extreme equity dilution. With Q2 2026 cash of $2.11M overwhelmed by quarterly cash burn of -$5.34M and $17.41M in debt, common shareholders face severe structural downside despite biodefense asset optionality.

7-factor investment score

Valion Bio Inc opportunities and risks

What speaks for VBIO

What speaks against VBIO

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
VBIOn/an/an/a516.0%12019.2%-1135.2%
VCNXn/a1.0xn/a98.3%-251.1%-321.7%
BRTXn/a6.1x0.1x92.1%-3089.6%-545.2%
REVBn/a0.0x0.8x0.0%0.0%-442.3%
ACUTn/a21.2xn/a100.0%-1680.0%-57.7%
SILOn/a26.1x0.4x-474.3%-8269.5%-236.8%
Peer mediann/a6.1x0.1x92.1%-1680.0%-321.7%

Frequently asked questions about Valion Bio Inc (VBIO)

Is VBIO stock a good investment?

The TradeMates model rates Valion Bio Inc as AVOID with an investment score of 11/100. Valion Bio faces critical liquidity depletion and extreme equity dilution. With Q2 2026 cash of $2.11M overwhelmed by quarterly cash burn of -$5.34M and $17.41M in debt, common shareholders face severe structural downside despite biodefense asset optionality. This is algorithmic model output, not personal investment advice.

Is VBIO stock a buy?

The TradeMates model verdict for VBIO is AVOID with an investment score of 11/100. Treat this as a model signal to review, not a personal buy recommendation.